Cosmetic and copper peptides compared

Melanotan 1 vs melanotan 2

A linear and a cyclic analog of alpha-melanocyte stimulating hormone, with each figure tied to its own label, study or regulator.

A 2006 review describes melanotan I as a linear peptide tested clinically for skin tanning and melanotan II as a cyclic truncated peptide tested for male erectile dysfunction.1 Melanotan I is [Nle4-D-Phe7]-α-MSH, and the Scenesse label gives afamelanotide the sequence with norleucine at the fourth place and D-phenylalanine at the seventh.2,3

Afamelanotide is labelled in the US as a 16 mg Scenesse implant for adults with phototoxic reactions from erythropoietic protoporphyria, and the TGA states that melanotan II is prescription-only in Australia and not approved as a tanning agent.3,4 No half-life of melanotan II measured in people was found.

FactMelanotan IMelanotan II
What it is[Nle4-D-Phe7]-α-MSH, a superpotent synthetic analog of α-MSH2; as afamelanotide, a synthetic peptide of 13 amino acids3A cyclic heptapeptide analog of α-MSH: Ac-Nle4-Asp5-His6-D-Phe7-Arg8-Trp9-Lys10 α-MSH4-10-NH29
How it comesScenesse: a 16 mg afamelanotide implant, inserted subcutaneously every 2 months3No product on the Australian register; seized nasal sprays labelled 30 MG held an estimated 22 mg to 54 mg per bottle4
Half-life
  • 0.8 to 1.7 hours for the beta phase after subcutaneous dosing, in 3 men6
  • About 15 hours from the Scenesse controlled release implant, on the US label3
No human half-life was found; in rats given 0.3 mg/kg intravenously, plasma levels showed biphasic disposition10
Studied doses
  • Pharmacokinetic trial: 0.08 to 0.21 mg/kg subcutaneously, in a crossover with 0.16 mg/kg intravenously and by mouth, in 3 men (ten doses over 2 weeks)6
  • US label: one 16 mg implant every 2 months3
  • Pilot phase I study: 0.01 mg/kg to start in 3 men, raised by 0.005 mg/kg steps to 0.025 or 0.03 mg/kg, subcutaneous9
  • Erectile dysfunction crossover study: 0.025 mg/kg and vehicle, twice each by subcutaneous injection, in 10 men11
StatusUS label (2019): pain free light exposure in adults with phototoxic reactions from erythropoietic protoporphyria3. EU authorisation on 22 December 20147. TGA: melanotan is not approved as a tanning agent in Australia8FDA lists it among substances withdrawn from category 2 by their nominators, naming immunogenicity and case reports of melanoma and priapism12. TGA: prescription-only, not approved as a tanning agent4

Get the app

Contents5
  1. 1How they differ
  2. 2Logged in Milligram
  3. 3What is not known
  4. 4References
  5. 5Related pages

Last reviewed . Sources are listed below.

How they differ

The Scenesse label states that afamelanotide binds predominantly to MC1-R and increases eumelanin in the skin independently of sunlight or artificial UV light.3 In a crossover study of 10 men with erectile dysfunction of no known organic cause, erections developed in 8 of 10 given melanotan II.5

In the melanotan I pharmacokinetic trial, the subcutaneous dose was completely bioavailable compared with the intravenous dose, and no drug was detected after oral dosing.6

Logged in Milligram

  • Melanotan I: Too few people logged it to show a share.
  • Melanotan II: 3% of people who logged a dose in Milligram logged it in the 90 days to 15 November 2026.

Shares of people who logged a dose in Milligram in the 90 days to 15 November 2026, shown only where at least 50 people logged three or more doses of the compound.

What is not known

The Scenesse label states that the effect of renal or hepatic impairment on afamelanotide's pharmacokinetics is unknown, and the EMA states that complete information on its benefits could not be obtained, in part because the disease is rare.3,7 The TGA states that melanotan tanning agents have not been assessed for quality or safety, and that melanotan II has been linked to reports of increased moles and freckles, kidney dysfunction and swelling of the brain.8 No study was found that gave both peptides in the same trial.

References

  1. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Journal article (review), Peptides 2006. PMID 16412534
  2. Dorr RT, Dvorakova K, Brooks C, Lines R, Levine N, Schram K, Miketova P, Hruby V, Alberts DS. Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans. Journal article (clinical trial), Photochem Photobiol 2000. PMID 11045725
  3. Clinuvel Inc. DailyMed - SCENESSE- afamelanotide implant. US prescribing information, 2026. DailyMed label
  4. Therapeutic Goods Administration (Australia). Melanotan II tanning peptide products found to be inconsistently dosed (safety advisory, 17 August 2026). Regulator safety advisory, 2026. tga.gov.au
  5. Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. Journal article (clinical trial), 1998. PMID 9679884
  6. Ugwu SO, Blanchard J, Dorr RT, Levine N, Brooks C, Hadley ME, Aickin M, Hruby VJ. Skin pigmentation and pharmacokinetics of melanotan-I in humans. Journal article (randomized crossover trial), Biopharm Drug Dispos 1997. PMID 9113347
  7. European Medicines Agency. Scenesse | European Medicines Agency (EMA). Regulator assessment summary, 2026. ema.europa.eu
  8. Therapeutic Goods Administration (Australia). Don't risk using tanning products containing melanotan. Regulator news article, 2025. tga.gov.au
  9. Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Journal article (clinical trial), 1996. PMID 8637402
  10. Ugwu SO, Blanchard J, Nguyen LD, Hadley ME, Dorr RT. A comparison of HPLC and bioassay methods for plasma melanotan-II (MT-II) determination: application to a pharmacokinetic study in rats. Journal article (animal pharmacokinetics), 1994. PMID 7981427
  11. Wessells H, Gralnek D, Dorr R, Hruby VJ, Hadley ME, Levine N. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Journal article (randomized controlled trial), 2000. PMID 11018622
  12. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Regulator web page, 2026. fda.gov